Vaccine makers and medicine regulators are sketching out plans in case the mutating coronavirus turns vaccine development into a game of cat and mouse.
Just weeks after leading manufacturers secured the first regulatory approvals, mutations in the virus have forced scientists to re-test their Covid-19 vaccines and prepare to tweak their formula should the shots prove less effective.
At the same time, regulators are considering how they could fast-track new approvals and whether they could use the seasonal flu jab as a model to authorise revised versions without requiring long trials.
您已阅读10%（590字），剩余90%（5348字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。